Abstracts tagged "Biologicals"

Abstract Number: 1267 • ACR Convergence 2023
Lower Herpes Zoster Rate of Tocilizumab and Tofacitinib in Patients Undergoing Treatment for Rheumatoid Arthritis
Yao fan Fang¹, Lai-Chu See² and Shu-Hao Chang², ¹Chang-Gung Memorial Hospital – Linkou, Taoyuan, Taiwan, ²Biostatistics Core Laboratory, Molecular Medicine Research centre, Chang Gung University, Taoyuan City, Taiwan
Background/Purpose: Biological disease-modifying antirheumatic drugs (bDMARDs) have become the primary treatment option for rheumatoid arthritis (RA) from 2010 in Taiwan. Tocilizumab is an interleukin-6 receptor…
Abstract Number: 1417 • ACR Convergence 2023
Do Long-term Patient-reported Outcomes Improve Similarly in Psoriatic Arthritis and Axial Spondyloarthritis Patients Treated with Secukinumab? Results from the EuroSpA Collaboration
Marion Pons¹, Simon Horskjær Rasmussen¹, Sara Nysom Christiansen¹, Brigitte Michelsen², Bente Glintborg¹, Bjorn Gudbjornsson³, Gerdur Maria Grondal⁴, Jiri Vencovsky⁵, Anne Gitte Loft⁶, Ziga Rotar⁷, Katja Perdan Pirkmajer⁸, Michael Nissen⁹, Burkhard Moeller¹⁰, Gary Macfarlane¹¹, Gareth T. Jones¹¹, Florenzo Iannone¹², Roberto F. Caporali¹³, Karin Laas¹⁴, Sigrid Vorobjov¹⁵, Daniela Di Giuseppe¹⁶, Belkis Nihan Coskun¹⁷, Burcu Yagız¹⁷, Sella Provan¹⁸, Karen Fagerli¹⁸, Isabel Castrejon¹⁹, Lucia Otero-Valera²⁰, Marleen van de Sande²¹, Irene van der Horst-Bruinsma²², Dan Nordstrom²³, Laura Kuusalo²⁴, Elsa Vieira-Sousa²⁵, Miguel Bernardes²⁶, Tor Olofsson²⁷, Jana Baranová²⁸, Merete Hetland¹, Mikkel Østergaard²⁹ and Lykke Ørnbjerg¹, ¹Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ²Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ⁵Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁶Aarhus University, Horsens, Denmark, ⁷University Medical Centre Ljubljana, Ljubljana, Slovenia, ⁸University Medical Centre Ljubljana; University of Ljubljana, Ljubljana, Slovenia, ⁹Geneva University Hospitals, Geneva, Switzerland, ¹⁰Inselspital - University Hospital Bern, Bern, Switzerland, ¹¹Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, United Kingdom, ¹²Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ¹⁴Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ¹⁵National Institute for Health Development, Tallinn, Estonia, ¹⁶Karolinska Institutet, Stockholm, Sweden, ¹⁷Department of Rheumatology, Bursa Uludag University, Bursa, Turkey, ¹⁸Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Hospital Universitario Gregorio Marañón, Madrid, Spain, ²⁰Spanish Society of Rheumatology, Madrid, Spain, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²³Helsinki University Hospital, Helsinki, Finland, ²⁴Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ²⁵Faculdade de Medicina da Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ²⁶Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ²⁷Lund University and Skåne University Hospital, Lund, Sweden, ²⁸Institute of Biostatistics and Analyses, Brno, Czech Republic, ²⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Patient reported outcomes (PROs) are important in the treatment evaluation of patients with spondyloarthritis, including axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). For secukinumab,…
Abstract Number: 1617 • ACR Convergence 2023
Comparing Uptake of Biosimilar Infliximab Among Patients with Medicare, Medicaid and Private Insurance in U.S. Rheumatology Practices 2016-2022
Eric Roberts¹, Jing Li¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski¹, Gabriela Schmajuk⁴ and Jinoos Yazdany¹, ¹University of California San Francisco, San Francisco, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, HI, ⁴UCSF / SFVA, San Francisco, CA
Background/Purpose: The first infliximab biosimilar (infliximab-dybb) entered the U.S. market in 2016, and two additional products have subsequently been introduced (infliximab-axxq (2017) and infliximab-abda (2020)).…
Abstract Number: 2113 • ACR Convergence 2023
Impact of Sociodemographic Factors on Efficacy and Safety of Tofacitinib in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 2/3/3b/4 Studies
Grace Wright¹, Eduardo Mysler², Kevin Roberts³, Lindsay Sweet⁴ and Ahmed Shelbaya⁵, ¹Grace C Wright MD PC, New York, NY, ²Organizacion Medica de Investigacion, Buenos Aires, Argentina, ³Pfizer Inc., Cambridge, MA, ⁴Pfizer Inc., Collegeville, PA, ⁵Pfizer Inc., New York, NY
Background/Purpose: Sociodemographic factors can impact treatment response and safety outcomes in patients (pts) with RA. Here, we explore the impact of sociodemographic index (SDI) on…
Abstract Number: 2231 • ACR Convergence 2023
Ixekizumab Significantly Improves Nail Disease and Adjacent Joint Tenderness and Swelling in Psoriatic Arthritis
Dennis McGonagle¹, Arthur Kavanaugh², Iain McInnes³, Lars Erik⁴, Joseph Merola⁵, Bruce Strober⁶, Rebecca Bolce⁷, Jeffrey Lisse⁷, Jennifer Pustizzi⁷, Christophe Sapin⁷ and Christopher T Ritchlin⁸, ¹Leeds Teaching Hospitals NHS Trust, Academic Unit for the Musculoskeletal Diseases, Leeds, United Kingdom, ²Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA, ³University of Glasgow, Glasgow, United Kingdom, ⁴Bispebjerg-Frederiksberg Hospital, Vedbæk, Denmark, ⁵Harvard Medical School, Brigham and Women's Hospital, Newton, MA, ⁶Yale University, New Haven, CT, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Nail psoriasis (PsO) is a strong predictor for the development of psoriatic arthritis (PsA) and has been reported in 63–83% of patients with PsA1.…
Abstract Number: 2347 • ACR Convergence 2023
Efficacy of Belimumab in Patients with Systemic Lupus Erythematosus by Race and Ethnicity: A Large Post Hoc Integrated Analysis of Five Clinical Trials
Saira Sheikh¹, Amit Saxena², Angela Carroll³, Christine Henning³, Julia HN Harris⁴, Bernard Rubin⁵, David D'Cruz⁶ and Alvin F Wells⁷, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²New York University Grossman School of Medicine, Rheumatology, New York, NY, ³GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁴GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁵GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁶Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom, ⁷Advocate Health Department of Rheumatology, Franklin, WI
Background/Purpose: Belimumab (BEL) is approved for the treatment of active SLE, and lupus nephritis, with standard therapy.1 The prevalence and severity of SLE tend to…
Abstract Number: 2551 • ACR Convergence 2023
Remission and Low Disease Activity (LDA) in Patients with SLE Treated with Belimumab (BEL): Results from a Large Integrated Analysis
Ioannis Parodis¹, Julius Lindblom¹, Roger A. Levy², Margherita Zen³, Nursen Cetrez¹, Alvaro Gomez⁴, Shereen Oon⁵, Christine Henning⁶, Munther Khamashta⁷, Holly A. Quasny⁸, Deven Chauhan⁹, Anca Askanase¹⁰, Ronald van Vollenhoven¹¹ and Mandana Nikpour¹², ¹Karolinska Institutet, Stockholm, Sweden, ²GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ³University of Padua, Division of Rheumatology, Department of Medicine, Padua, Italy, ⁴Karolinska Institutet and Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, ⁵University of Melbourne at St Vincent’s Hospital, Departments of Rheumatology and Medicine, Fitzroy, Australia, ⁶GlaxoSmithKline, US Medical Affairs, Durham, NC, ⁷GSK Gulf, Medical Affairs Department, Dubai, United Arab Emirates, ⁸GlaxoSmithKline, Research & Development, Durham, NC, ⁹GlaxoSmithKline, Value Evidence and Outcomes, Brentford, United Kingdom, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands, ¹²The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia
Background/Purpose: A key treatment goal in SLE management is the attainment of remission or LDA,1 for which various definitions exist, including “Definitions of Remission in…
Abstract Number: 0078 • ACR Convergence 2023
Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Are Elevated in Patients with Rheumatoid Arthritis and Predict Treatment Response to Abatacept or TNF Blockers
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal¹, Irene Monjo², Mariela Uyaguari-Morocho¹, Alejandro Villalba³, Laura Nuño¹, Diana Peiteado¹, Elisa Fernández¹, Sara García-Carazo¹ and Alejandro Balsa⁴, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²University Hospital La Paz, Madrid, Spain, ³Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: CD4+CXCR5+PD-1hi follicular helper (Tfh) T cells dwell in the germinal centers (GCs), help B cells, and are implicated in Rheumatoid Arthritis (RA) pathogenesis. Circulating…
Abstract Number: 0391 • ACR Convergence 2023
Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapää-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹⁰, Virginia Pascual Ramos¹¹, Irazú Contreras Yañez¹², Iris Colunga¹³, Dionicio A. Galarza-Delgado¹³, José Ramón Azpiri-López¹³, Silvia Rolefstad¹⁴, Anne Grete Semb¹⁵, Durga P Misra¹⁶, Ellen Margrethe Hauge¹⁷ and GEORGE KITAS¹⁸, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹³Hospital Universitario UANL, Monterrey, Mexico, ¹⁴Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁵Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁷Aarhus University Hospital, Aarhus, Denmark, ¹⁸The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Chronic inflammation contributes to enhanced cardiovascular risk in rheumatoid arthritis (RA). Biologic disease modifying antirheumatic drugs (bDMARDs) control inflammation in many conventional synthetic DMARD…
Abstract Number: 0529 • ACR Convergence 2023
Sex-dependent Differences in Disease Characteristics Do Not Influence Effectiveness of Secukinumab Therapy in Patients with Active Axial Spondyloarthritis in a Non-Interventional Trial (AQUILA)
Michaela Koehm¹, Maximilian Klippstein², Sabine Kugler³, Sina Mackay³, Daniel Schulz³, Asmir Vodencarevic⁴, Guillaume Wendt⁴, Daniel Peterlik⁴, Uta Kiltz⁵, Jan Brandt-Juergens⁶ and Frank Behrens⁷, ¹University Hospital Frankfurt, Frankfurt, Germany, ²Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Frankfurt, Germany, ³Fraunhofer Institute for Intelligent Analysis and Information Systems IAIS, Fraunhofer Cluster of Excellence Immune Mediated Diseases CIMD, Sankt Augustin, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany, ⁵Rheumazentrum Ruhrgebiet, Herne, Germany, ⁶rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Goethe-University & Fraunhofer ITMP, Frankfurt, Germany
Background/Purpose: Individualized treatment strategies are of high importance in the treatment of patients with axial spondyloarthritis (axSpA). IL-17A inhibition has demonstrated good efficacy on axSpA.…
Abstract Number: 0675 • ACR Convergence 2023
Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
allyson egan¹, Pasupathy Sivasothy² and David Jayne³, ¹Trinity Health Kidney Centre, Tallaght University Hospital, Ireland, Dublin, Ireland, ²Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom, ³University of Cambridge, Cambridge, United Kingdom
Background/Purpose: In the randomized, placebo-controlled MIRRA trial for relapsing and refractory eosinophilic granulomatosis with polyangiitis (EGPA), adjuvant therapy with 300mg anti-IL5 mAB Mepolizumab [MEPO] for…
Abstract Number: 1045 • ACR Convergence 2023
Ultrasound Findings in Patients with Difficult to Treat Rheumatoid Arthritis
Tadashi Okano¹, Kenji Mamoto¹, Yutaro Yamada¹, Shohei Anno², Asami Yagami¹, Yuka Domae¹, Shingo Washida¹, Yuko Yoshida¹, Tatsuya Koike³ and Hiroaki Nakamura¹, ¹Osaka Metropolitan University, Osaka, Japan, ²Yodogawa Christian Hospital, Osaka, Japan, ³Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama Foundation for Health and Welfare, Shirahama, Japan
Background/Purpose: In recent years, the concept of D2T RA (difficult-to-treat rheumatoid arthritis) has become widespread, and D2T RA patients are defined as a state in…
Abstract Number: 1299 • ACR Convergence 2023
Rheumatoid Arthritis Patients Who Never Use a Biological During Their Disease Course Represent a Subgroup of Patients Likely to Achieve Sustained DMARD-free Remission
Judith Heutz¹, Pascal de Jong¹, Annette van der Helm-van Mil² and Elise van Mulligen¹, ¹Erasmus Medical Center, Rotterdam, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: According to the 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) complete cessation of DMARDs is not advisable due to a high…
Abstract Number: 1424 • ACR Convergence 2023
Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub-Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naïve Patients
Dafna Gladman¹, Xenofon Baraliakos², Michael Starr³, Roberto Ranza⁴, Emmanouil Rampakakis⁵, Natalie shiff⁶, Francois Nantel⁷, Chenglong Han⁸, Andrew James Knowles Ostor⁹ and Philip J. Mease¹⁰, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ³Division of Rheumatology, McGill University Health Center, Montreal, QC, Canada, ⁴Rheumatology Unit, Hospital das Clínicas da Universidade Federal de Uberlândia, Uberlândia, Brazil, ⁵McGill University, Department of Pediatrics / JSS Medical Research, Scientific Affairs, Montreal, QC, Canada, ⁶Immunology, Janssen Scientific Affairs, LLC / Adjunct, Community Health and Epidemiology, University of Saskatchewan, Horsham, PA, ⁷Nantel Medsci Consult, Consultant, Montreal, QC, Canada, ⁸Immunology, Janssen Global Services, LLC, Malvern, PA, ⁹Cabrini Hospital, Monash University & Emeritus Research / Australian National University, Canberra, Australia, ¹⁰Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Fatigue is commonly reported by PsA patients (pts) and contributes to disease burden. The fully human IL-23p19-subunit inhibitor guselkumab (GUS) induces clinically meaningful and…
Abstract Number: 1674 • ACR Convergence 2023
Severe Infections in Patients with VEXAS Syndrome: A Study from the French VEXAS Group
Benjamin de Valence de Minardiere¹, Marion Delaune², Yann Nguyen³, Vincent Jachiet⁴, Mael Heiblig⁵, Alexis Jean⁶, Pierrick Henneton⁷, stanislas Riescher-tuczkiewicz⁸, Philippe Guilpain⁷, Hervé Lobbes⁹, Guillaume Le Guenno¹⁰, Nicolas Schleinitz¹¹, Valentin Lacombe¹², Vincent Langlois¹³, Roderau Outh¹⁴, Julien Vinit¹⁵, Jean-Philippe Martellosio¹⁶, Paul Decker¹⁷, Alexandre Vlakos¹⁸, Thomas Moulinet¹⁹, Yannick Dieudonne²⁰, Adrien Bigot²¹, Louis Terriou²², Bertrand De Maleprade²³, Guillaume Denis²⁴, Jonathan Broner²⁵, Marie Kostine²⁶, Sébastien Humbert²⁷, Benjamin Terrier²⁸, Sophie Georgin-Lavialle²⁹, Olivier Fain³⁰, Arsène Mekinian¹, Marjolaine MORGAND¹, Thibault Comont² and Jerome Hadjadj¹, ¹Department of Internal Medicine, Hôpital Saint-Antoine, AP-HP, Paris, France, ²Toulouse University Hospital, Toulouse, France, ³Department of Internal Medicine, Hôpital Beaujon, AP-HP, Clichy, France., Montmorency, France, ⁴Service de médecine interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Sorbonne Université, AP-HP, Hôpital Saint Antoine, Paris, France, ⁵Hematology, Hospices Civils de Lyon, Lyon-Sud Hospital, Pierre-Bénite, France, ⁶Internal Medicine Department, Bordeaux University, Faculty of Medicine, Bordeaux University Hospital, Bordeaux, France, ⁷CHU Montpellier, Montpellier, France, ⁸CHU de Nantes, Nantes, France, ⁹CHU de Clermont-Ferrand, Clermont-Ferrand, France, ¹⁰Internal Medicine Department, Clermont-Ferrand University, Faculty of Medicine, Estaing University Hospital, Clermont-Ferrand, France, ¹¹Aix Marseille university, AP-HM, Marseille, France, ¹²Internal Medicine Department, Anger Hospital, Clermont-Ferrand, France, ¹³Service de Médecine Interne, Hôpital Jacques Monod, Le Havre, France, ¹⁴Internal Medicine Department, Perpignan Hospital Center, Perpignan, France, ¹⁵Service de Médecine Interne, CH William Morey, Chalon sur Saône, France., Chalon sur Saône, France, ¹⁶Service de médecine interne, maladies infectieuses et tropicales, CHU de Poitiers, Poitiers, France, ¹⁷Nancy hospital, France, Nancy, France, ¹⁸Vesoul Hospital, Vesoul, France, ¹⁹Department of Internal Medicine, Centre hospitalier universitaire de Nancy, Nancy, France, ²⁰Department of Clinical Immunology and Internal Medicine, National Reference Centre for Systemic Autoimmune Diseases (CNR RESO), Strasbourg University Hospital, Strasbourg, France, ²¹Internal Medicine Department, Tours University, Faculty of Medicine, Tours University Hospital, Tours, France, ²²Service de Médecine Interne et Immunologie Clinique, CHU Lille, Lille, France, ²³Rouen hospital, France, Rouen, France, ²⁴Service d'hématologie, CH de Rochefort, Rochefort, France, ²⁵CHU de Nimes, Nimes, France, ²⁶Bordeaux University Hospital, Bordeaux, France, ²⁷Besançon University Hospital, Besançon, France, ²⁸Department of Internal Medicine, Hôpital Cochin, AP-HP, Paris, France, ²⁹AP-HP, Tenon hospital, Paris, France, ³⁰Hopital SAINT ANTOINE APHP, Paris, France
Background/Purpose: VEXAS (Vacuoles, E1 Enzyme, X-Linked, Autoinflammatory, Somatic) syndrome is an autoinflammatory monogenic disease caused by inactivating somatic mutations in the UBA1 gene and characterized…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].